At least in experimental animals the efficacy of active immunotherapy of cancer can be increased by metabolic reprogramming of tumor antigen (TA)-specific CD8+ T cells towards fatty acid (FA) catabolism and away from glycolysis [1]. The gene discussed is CD8A; the disease is cancer.